FDA clears Corgenix' tests for thrombosis risk:
This article was originally published in Clinica
Executive Summary
Corgenix Medical's IgG anti-Prothrombin and IgM anti-Prothrombin antibody test kits are for the diagnosis and risk assessment of certain cardiovascular disorders characterised by blood clot formation. The tests will be added to the Denver, Colorado company's range of ELISA-based diagnostic assays for antiphospholipid antibodies.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.